Mauna Kea Technologies Reports Strong Q1 2026 Core Sales Growth

PARIS & BOSTON--(BUSINESS WIRE)--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, today reported its revenue for the first quarter of 2026. Sacha Loiseau, Ph.D., Chairman and CEO of Mauna Kea Technologies, commented: "Our Q1 2026 performance confirms the robust growth trajectory initiated in the U.S. in 2025, which is now expanding internationally. This momentum.